木子文文仔的个人主页 - 老虎社区

木子文文仔

暂无个人介绍

IP属地：0

2关注

0粉丝

0主题

0勋章

木子文文仔

2025-08-28

说说你对这篇新闻的看法...

Outlook Therapeutics就FDA审查Ons-5010/Lytenava™(Bevacizumab-Vikg)湿性AMD治疗药物提供监管进展更新

木子文文仔

2025-07-14

这篇文章不错，转发给大家看看

@oliv:$英伟达(NVDA)$ 差不多了吧

木子文文仔

2025-07-10

是真的牛逼啊，这公司跑路了？

皮肤管理公司朴荷生物暴跌超92%创IPO以来新低，该股此前年内累涨超500%

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"4099625154861370","uuid":"4099625154861370","gmtCreate":1636522087803,"gmtModify":1636522087803,"name":"木子文文仔","pinyin":"mzwwzmuziwenwenzai","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.laohu8.com/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":2,"tweetSize":3,"questionSize":0,"limitLevel":999,"accountStatus":2,"level":{"id":0,"name":"","nameTw":"","represent":"","factor":"","iconColor":"","bgColor":""},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-3","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"偶像虎友","description":"加入老虎社区1500天","bigImgUrl":"https://static.tigerbbs.com/8b40ae7da5bf081a1c84df14bf9e6367","smallImgUrl":"https://static.tigerbbs.com/f160eceddd7c284a8e1136557615cfad","grayImgUrl":"https://static.tigerbbs.com/11792805c468334a9b31c39f95a41c6a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.12.20","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001}],"userBadgeCount":1,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":1,"crmLevelSwitch":0,"location":"0","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":472456070021664,"gmtCreate":1756377607097,"gmtModify":1756379405949,"author":{"id":"4099625154861370","authorId":"4099625154861370","name":"木子文文仔","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4099625154861370","idStr":"4099625154861370"},"themes":[],"htmlText":"说说你对这篇新闻的看法...","listText":"说说你对这篇新闻的看法...","text":"说说你对这篇新闻的看法...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/472456070021664","repostId":"1155673207","repostType":2,"repost":{"id":"1155673207","kind":"news","weMediaInfo":{"introduction":"全球快讯第一时间播报","home_visible":1,"media_name":"美股速递","id":"1004306016","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"pubTimestamp":1756377034,"share":"https://www.laohu8.com/m/news/1155673207?lang=zh_CN&edition=full","pubTime":"2025-08-28 18:30","market":"us","language":"zh","title":"Outlook Therapeutics就FDA审查Ons-5010/Lytenava™(Bevacizumab-Vikg)湿性AMD治疗药物提供监管进展更新","url":"https://stock-news.laohu8.com/highlight/detail?id=1155673207","media":"美股速递","summary":"Outlook Therapeutics就美国食品药品监督管理局审查其Ons-5010/Lytenava™(Bevacizumab-Vikg)湿性年龄相关性黄斑变性治疗药物的情况提供了监管进展更新。","content":"<p>Outlook Therapeutics就美国食品药品监督管理局审查其Ons-5010/Lytenava™(Bevacizumab-Vikg)湿性年龄相关性黄斑变性治疗药物的情况提供了监管进展更新。</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Outlook Therapeutics就FDA审查Ons-5010/Lytenava™(Bevacizumab-Vikg)湿性AMD治疗药物提供监管进展更新</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOutlook Therapeutics就FDA审查Ons-5010/Lytenava™(Bevacizumab-Vikg)湿性AMD治疗药物提供监管进展更新\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1004306016\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">美股速递 </p>\n<p class=\"h-time\">2025-08-28 18:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Outlook Therapeutics就美国食品药品监督管理局审查其Ons-5010/Lytenava™(Bevacizumab-Vikg)湿性年龄相关性黄斑变性治疗药物的情况提供了监管进展更新。</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OTLK":"Outlook Therapeutics, Inc.","BK4139":"生物科技"},"source_url":"","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1155673207","content_text":"Outlook Therapeutics就美国食品药品监督管理局审查其Ons-5010/Lytenava™(Bevacizumab-Vikg)湿性年龄相关性黄斑变性治疗药物的情况提供了监管进展更新。","news_type":1,"symbols_score_info":{"OTLK":1}},"isVote":1,"tweetType":1,"viewCount":812,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":456333061746736,"gmtCreate":1752446714357,"gmtModify":1752456006743,"author":{"id":"4099625154861370","authorId":"4099625154861370","name":"木子文文仔","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4099625154861370","idStr":"4099625154861370"},"themes":[],"htmlText":"这篇文章不错，转发给大家看看","listText":"这篇文章不错，转发给大家看看","text":"这篇文章不错，转发给大家看看","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/456333061746736","repostId":"455539964727560","repostType":1,"repost":{"id":455539964727560,"gmtCreate":1752253092211,"gmtModify":1752253094563,"author":{"id":"3572904085072563","authorId":"3572904085072563","name":"oliv","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3572904085072563","idStr":"3572904085072563"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/NVDA\">$英伟达(NVDA)$&nbsp;</a><v-v data-views=\"1\"></v-v> 差不多了吧","listText":"<a href=\"https://laohu8.com/S/NVDA\">$英伟达(NVDA)$&nbsp;</a><v-v data-views=\"1\"></v-v> 差不多了吧","text":"$英伟达(NVDA)$ 差不多了吧","images":[{"img":"https://static.tigerbbs.com/5339648cf63f58dd338126590e834f2d","width":"981","height":"1637"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/455539964727560","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":1039,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":454992418140440,"gmtCreate":1752100411498,"gmtModify":1752109558235,"author":{"id":"4099625154861370","authorId":"4099625154861370","name":"木子文文仔","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4099625154861370","idStr":"4099625154861370"},"themes":[],"htmlText":"是真的牛逼啊，这公司跑路了？","listText":"是真的牛逼啊，这公司跑路了？","text":"是真的牛逼啊，这公司跑路了？","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/454992418140440","repostId":"1190080640","repostType":2,"repost":{"id":"1190080640","kind":"news","weMediaInfo":{"introduction":"为用户提供金融资讯、行情、数据，旨在帮助投资者理解世界，做投资决策。","home_visible":1,"media_name":"老虎资讯综合","id":"102","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1752016224,"share":"https://www.laohu8.com/m/news/1190080640?lang=zh_CN&edition=full","pubTime":"2025-07-09 07:10","market":"hk","language":"zh","title":"皮肤管理公司朴荷生物暴跌超92%创IPO以来新低，该股此前年内累涨超500%","url":"https://stock-news.laohu8.com/highlight/detail?id=1190080640","media":"老虎资讯综合","summary":"在美上市皮肤管理公司朴荷生物（ $Park Ha Biological Technology Co. Ltd.(PHH)$ ，PHH）周二暴跌超92%，报2.99美元，创2024年12月美国IPO以来新低。至7月7日收盘的年内累计涨幅为552%，当天股价创历史新高、盘中市值一度达到11亿美元。公开资料显示，朴荷生物成立于2022年10月，总部位于江苏无锡，主营业务涵盖自有护肤品牌、直接销售护肤品，以及特许经营服务。其中，朴荷生物旗下品牌“Park Ha”，创立于2016年，并在2017年开设首家门店，致力于为各种皮肤问题的消费者提供解决方案。","content":"<html><head></head><body><p>在美上市皮肤管理公司朴荷生物（ <a href=\"https://laohu8.com/S/PHH\">Park Ha Biological Technology Co. Ltd.</a> ，PHH）周二暴跌超92%，报2.99美元，创2024年12月美国IPO以来新低。</p><p>至7月7日收盘的年内累计涨幅为552%，当天股价创历史新高、盘中市值一度达到11亿美元。</p><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/2fed4308c05660972512d46183750d9c\" tg-width=\"560\" tg-height=\"240\"/></p><p>公开资料显示，朴荷生物成立于2022年10月，总部位于江苏无锡，主营业务涵盖自有护肤品牌、直接销售护肤品，以及特许经营服务。其中，朴荷生物旗下品牌“Park Ha”，创立于2016年，并在2017年开设首家门店，致力于为各种皮肤问题的消费者提供解决方案。</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>皮肤管理公司朴荷生物暴跌超92%创IPO以来新低，该股此前年内累涨超500%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n皮肤管理公司朴荷生物暴跌超92%创IPO以来新低，该股此前年内累涨超500%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/102\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">老虎资讯综合 </p>\n<p class=\"h-time\">2025-07-09 07:10</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>在美上市皮肤管理公司朴荷生物（ <a href=\"https://laohu8.com/S/PHH\">Park Ha Biological Technology Co. Ltd.</a> ，PHH）周二暴跌超92%，报2.99美元，创2024年12月美国IPO以来新低。</p><p>至7月7日收盘的年内累计涨幅为552%，当天股价创历史新高、盘中市值一度达到11亿美元。</p><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/2fed4308c05660972512d46183750d9c\" tg-width=\"560\" tg-height=\"240\"/></p><p>公开资料显示，朴荷生物成立于2022年10月，总部位于江苏无锡，主营业务涵盖自有护肤品牌、直接销售护肤品，以及特许经营服务。其中，朴荷生物旗下品牌“Park Ha”，创立于2016年，并在2017年开设首家门店，致力于为各种皮肤问题的消费者提供解决方案。</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/3299f0aa430f44d45729a266d0f7b350","relate_stocks":{},"source_url":"","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1190080640","content_text":"在美上市皮肤管理公司朴荷生物（ Park Ha Biological Technology Co. Ltd. ，PHH）周二暴跌超92%，报2.99美元，创2024年12月美国IPO以来新低。至7月7日收盘的年内累计涨幅为552%，当天股价创历史新高、盘中市值一度达到11亿美元。公开资料显示，朴荷生物成立于2022年10月，总部位于江苏无锡，主营业务涵盖自有护肤品牌、直接销售护肤品，以及特许经营服务。其中，朴荷生物旗下品牌“Park Ha”，创立于2016年，并在2017年开设首家门店，致力于为各种皮肤问题的消费者提供解决方案。","news_type":1,"symbols_score_info":{"PHH":1.1}},"isVote":1,"tweetType":1,"viewCount":1564,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"hots":[{"id":472456070021664,"gmtCreate":1756377607097,"gmtModify":1756379405949,"author":{"id":"4099625154861370","authorId":"4099625154861370","name":"木子文文仔","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4099625154861370","idStr":"4099625154861370"},"themes":[],"htmlText":"说说你对这篇新闻的看法...","listText":"说说你对这篇新闻的看法...","text":"说说你对这篇新闻的看法...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/472456070021664","repostId":"1155673207","repostType":2,"repost":{"id":"1155673207","kind":"news","weMediaInfo":{"introduction":"全球快讯第一时间播报","home_visible":1,"media_name":"美股速递","id":"1004306016","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"pubTimestamp":1756377034,"share":"https://www.laohu8.com/m/news/1155673207?lang=zh_CN&edition=full","pubTime":"2025-08-28 18:30","market":"us","language":"zh","title":"Outlook Therapeutics就FDA审查Ons-5010/Lytenava™(Bevacizumab-Vikg)湿性AMD治疗药物提供监管进展更新","url":"https://stock-news.laohu8.com/highlight/detail?id=1155673207","media":"美股速递","summary":"Outlook Therapeutics就美国食品药品监督管理局审查其Ons-5010/Lytenava™(Bevacizumab-Vikg)湿性年龄相关性黄斑变性治疗药物的情况提供了监管进展更新。","content":"<p>Outlook Therapeutics就美国食品药品监督管理局审查其Ons-5010/Lytenava™(Bevacizumab-Vikg)湿性年龄相关性黄斑变性治疗药物的情况提供了监管进展更新。</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Outlook Therapeutics就FDA审查Ons-5010/Lytenava™(Bevacizumab-Vikg)湿性AMD治疗药物提供监管进展更新</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOutlook Therapeutics就FDA审查Ons-5010/Lytenava™(Bevacizumab-Vikg)湿性AMD治疗药物提供监管进展更新\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1004306016\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">美股速递 </p>\n<p class=\"h-time\">2025-08-28 18:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Outlook Therapeutics就美国食品药品监督管理局审查其Ons-5010/Lytenava™(Bevacizumab-Vikg)湿性年龄相关性黄斑变性治疗药物的情况提供了监管进展更新。</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OTLK":"Outlook Therapeutics, Inc.","BK4139":"生物科技"},"source_url":"","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1155673207","content_text":"Outlook Therapeutics就美国食品药品监督管理局审查其Ons-5010/Lytenava™(Bevacizumab-Vikg)湿性年龄相关性黄斑变性治疗药物的情况提供了监管进展更新。","news_type":1,"symbols_score_info":{"OTLK":1}},"isVote":1,"tweetType":1,"viewCount":812,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":456333061746736,"gmtCreate":1752446714357,"gmtModify":1752456006743,"author":{"id":"4099625154861370","authorId":"4099625154861370","name":"木子文文仔","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4099625154861370","idStr":"4099625154861370"},"themes":[],"htmlText":"这篇文章不错，转发给大家看看","listText":"这篇文章不错，转发给大家看看","text":"这篇文章不错，转发给大家看看","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/456333061746736","repostId":"455539964727560","repostType":1,"repost":{"id":455539964727560,"gmtCreate":1752253092211,"gmtModify":1752253094563,"author":{"id":"3572904085072563","authorId":"3572904085072563","name":"oliv","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3572904085072563","idStr":"3572904085072563"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/NVDA\">$英伟达(NVDA)$&nbsp;</a><v-v data-views=\"1\"></v-v> 差不多了吧","listText":"<a href=\"https://laohu8.com/S/NVDA\">$英伟达(NVDA)$&nbsp;</a><v-v data-views=\"1\"></v-v> 差不多了吧","text":"$英伟达(NVDA)$ 差不多了吧","images":[{"img":"https://static.tigerbbs.com/5339648cf63f58dd338126590e834f2d","width":"981","height":"1637"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/455539964727560","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":1039,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":454992418140440,"gmtCreate":1752100411498,"gmtModify":1752109558235,"author":{"id":"4099625154861370","authorId":"4099625154861370","name":"木子文文仔","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4099625154861370","idStr":"4099625154861370"},"themes":[],"htmlText":"是真的牛逼啊，这公司跑路了？","listText":"是真的牛逼啊，这公司跑路了？","text":"是真的牛逼啊，这公司跑路了？","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/454992418140440","repostId":"1190080640","repostType":2,"repost":{"id":"1190080640","kind":"news","weMediaInfo":{"introduction":"为用户提供金融资讯、行情、数据，旨在帮助投资者理解世界，做投资决策。","home_visible":1,"media_name":"老虎资讯综合","id":"102","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1752016224,"share":"https://www.laohu8.com/m/news/1190080640?lang=zh_CN&edition=full","pubTime":"2025-07-09 07:10","market":"hk","language":"zh","title":"皮肤管理公司朴荷生物暴跌超92%创IPO以来新低，该股此前年内累涨超500%","url":"https://stock-news.laohu8.com/highlight/detail?id=1190080640","media":"老虎资讯综合","summary":"在美上市皮肤管理公司朴荷生物（ $Park Ha Biological Technology Co. Ltd.(PHH)$ ，PHH）周二暴跌超92%，报2.99美元，创2024年12月美国IPO以来新低。至7月7日收盘的年内累计涨幅为552%，当天股价创历史新高、盘中市值一度达到11亿美元。公开资料显示，朴荷生物成立于2022年10月，总部位于江苏无锡，主营业务涵盖自有护肤品牌、直接销售护肤品，以及特许经营服务。其中，朴荷生物旗下品牌“Park Ha”，创立于2016年，并在2017年开设首家门店，致力于为各种皮肤问题的消费者提供解决方案。","content":"<html><head></head><body><p>在美上市皮肤管理公司朴荷生物（ <a href=\"https://laohu8.com/S/PHH\">Park Ha Biological Technology Co. Ltd.</a> ，PHH）周二暴跌超92%，报2.99美元，创2024年12月美国IPO以来新低。</p><p>至7月7日收盘的年内累计涨幅为552%，当天股价创历史新高、盘中市值一度达到11亿美元。</p><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/2fed4308c05660972512d46183750d9c\" tg-width=\"560\" tg-height=\"240\"/></p><p>公开资料显示，朴荷生物成立于2022年10月，总部位于江苏无锡，主营业务涵盖自有护肤品牌、直接销售护肤品，以及特许经营服务。其中，朴荷生物旗下品牌“Park Ha”，创立于2016年，并在2017年开设首家门店，致力于为各种皮肤问题的消费者提供解决方案。</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>皮肤管理公司朴荷生物暴跌超92%创IPO以来新低，该股此前年内累涨超500%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n皮肤管理公司朴荷生物暴跌超92%创IPO以来新低，该股此前年内累涨超500%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/102\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">老虎资讯综合 </p>\n<p class=\"h-time\">2025-07-09 07:10</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>在美上市皮肤管理公司朴荷生物（ <a href=\"https://laohu8.com/S/PHH\">Park Ha Biological Technology Co. Ltd.</a> ，PHH）周二暴跌超92%，报2.99美元，创2024年12月美国IPO以来新低。</p><p>至7月7日收盘的年内累计涨幅为552%，当天股价创历史新高、盘中市值一度达到11亿美元。</p><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/2fed4308c05660972512d46183750d9c\" tg-width=\"560\" tg-height=\"240\"/></p><p>公开资料显示，朴荷生物成立于2022年10月，总部位于江苏无锡，主营业务涵盖自有护肤品牌、直接销售护肤品，以及特许经营服务。其中，朴荷生物旗下品牌“Park Ha”，创立于2016年，并在2017年开设首家门店，致力于为各种皮肤问题的消费者提供解决方案。</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/3299f0aa430f44d45729a266d0f7b350","relate_stocks":{},"source_url":"","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1190080640","content_text":"在美上市皮肤管理公司朴荷生物（ Park Ha Biological Technology Co. Ltd. ，PHH）周二暴跌超92%，报2.99美元，创2024年12月美国IPO以来新低。至7月7日收盘的年内累计涨幅为552%，当天股价创历史新高、盘中市值一度达到11亿美元。公开资料显示，朴荷生物成立于2022年10月，总部位于江苏无锡，主营业务涵盖自有护肤品牌、直接销售护肤品，以及特许经营服务。其中，朴荷生物旗下品牌“Park Ha”，创立于2016年，并在2017年开设首家门店，致力于为各种皮肤问题的消费者提供解决方案。","news_type":1,"symbols_score_info":{"PHH":1.1}},"isVote":1,"tweetType":1,"viewCount":1564,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"lives":[]}